285 results on '"Friberg, Lena E."'
Search Results
2. Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli
3. Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia
4. Publisher Correction: Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
5. Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
6. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
7. Integration of individual preclinical and clinical anti‐infective PKPD data to predict clinical study outcomes.
8. Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib
9. Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice
10. Considerations for the optimal management of antibiotic therapy in elderly patients
11. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes
12. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy
13. A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology
14. Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies
15. Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
16. Multistate modeling for survival analysis in critically ill patients treated with meropenem.
17. Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models
18. Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii
19. A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
20. Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
21. Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors
22. Bayesian forecasting of tumor size metrics and overall survival
23. Research priorities towards precision antibiotic therapy to improve patient care
24. Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase
25. Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections
26. Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents
27. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling
28. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
29. Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance
30. Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.
31. Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors.
32. Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout
33. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
34. Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
35. Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever
36. Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
37. Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis
38. A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
39. Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever.
40. Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
41. Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel
42. CPT: Pharmacometrics & Systems Pharmacology – Inception, Maturation, and Future Vision
43. Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
44. Dose response of whole-grain biomarkers: alkylresorcinols in human plasma and their metabolites in urine in relation to intake
45. Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings.
46. Predictions of In Vivo Prolactin Levels from In Vitro K i Values of D2 Receptor Antagonists Using an Agonist–Antagonist Interaction Model
47. Dr. Hartmut Derendorf, PhD, a world‐renowned expert in pharmacokinetics and pharmacometrics (1953–2020)
48. Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel
49. Characterizing variability in warfarin dose requirements in children using modelling and simulation
50. Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework: A Quantitative Modeling Framework
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.